• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Catalent Biologics Completes Madison Expansion

    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Lilly Modifies Purchase Agreement with U.S. for COVID Therapies
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Catalent Biologics Completes Madison Expansion

    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Digitalization and the Future of Formulating in Modern R&D Labs
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Reed-Lane

    Baxter BioPharma Solutions

    Almac Group

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Emergent BioSolutions

    Quotient Sciences

    PCI Pharma Services

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Process Validation in Biologics Development

    Strategies for successful process validation in the wake of faster approval timelines.

    Process Validation in Biologics Development
    Process Validation in Biologics Development
    Table 1: Typical CQAs for a monoclonal antibody
    Process Validation in Biologics Development
    Table 2: Example Study Recommendations and Supporting Analytical Requirements
    Process Validation in Biologics Development
    Figure 1: Filing and Approval – General Timeline for Large Molecule Drug Substance (DS) and Drug Product (DP)
    Related CONTENT
    • Eurofins PSS Insourcing Solutions
    • Mogene
    • Vetio Animal Health
    • 5 ADC Manufacturing Challenges You Need To Know
    • Nitrosamines
    Victor Vinci and Claudia Berdugo-Davis, Catalent Biologics05.07.19
    The journey from an initial idea through to approval is challenging for any new medicine. Once a promising clinical lead has been chosen, the next step is to make GMP-quality material in larger quantities, using processes that are both robust and reproducible. While this can be difficult for a small molecule drug, it can be even more challenging for a biological drug because of the complex nature of the recombinant protein. It is, therefore, essential that the manufacturing process reliably makes batches that meet product specifications, every time.

    Process validation is an important step for potential therapies that have had early success in the clinic and are progressing toward commercial manufacturing. The process validation strategy should be informed by validation guidelines laid down by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). For example, the 2011 FDA validation guideline1 frames the three stages of validation as a continuum. This article will present a template for a repeatable late-phase development approach that leverages prior knowledge to speed timelines and enable the best chance of success.

    At the beginning of Stage 1, when the molecule moves into development, a target product profile (TPP) has been defined that stipulates the attributes of the molecule that will make it an acceptable drug, considering both its safety and its efficacy. During Stage 1, a process is designed and defined that will allow clinical manufacturing of batches that are sufficiently large to supply Phase 1 and Phase 2 trials. This process should be carefully characterized to provide an insight into how the process (parameters and inputs) links to the chemical and physical attributes of the molecule that is being made.

    In Stage 2, the growing knowledge about both process and product are elaborated upon, with the final stages of manufacturing equipment and facility qualification and process performance qualification (PPQ) being carried out. This will show whether the process is sufficiently robust to make the drug molecule consistently, and the data and control strategy will be part of the biological license application (BLA) filing for the drug. This is also the point at which the commercial manufacturing and life-cycle of the product should be considered in detail in preparation for commercial manufacturing, which occurs in Stage 3.

    Regulatory strategy for process validation
    ICH Q82 is a pivotal document, being one of the first to lay out the requirements for Quality by Design (QbD). This is a process which links what is known about the molecule, both in terms of its structure and its activity, creating the TPP, which leads to the definition of the product’s critical quality attributes (CQAs). These are the attributes of the molecule that can be measured and tested and are linked to patient safety and efficacy. It also contains risk assessments that include raw material attributes. This control strategy should cover everything that is added to the biomanufacturing process, including media and other components of the cell culture, materials required for the drug’s purification, and any excipients that are required for the drug product formulation.

    The TPP is used to inform the late-phase design space, and the information and knowledge about the process is considered from the molecule’s standpoint to identify which aspects are critical, and how they might be controlled to ensure compliance and reproducibility. This control strategy, which is a crucial part of the regulatory filing, expresses how product specifications will be controlled, and also forms a part of the product’s life-cycle, offering an opportunity for constant process verification and continual improvement.

    Previous experience with similar molecules can, and should, be used to inform these decisions. Whether the molecule in question is a monoclonal antibody, a fusion protein, or some other form of molecule produced by DNA expression, there is already a wealth of experience in testing and establishing stability. Initial results from in vitro and in vivo studies on the molecule, and early clinical safety and efficacy data, can also be invaluable here. This can all be linked to the product attributes, with a criticality assessment. All this information will inform the thinking about which critical quality attributes need to be controlled, how manufacturing will ensure that there is sufficient control, and how it will be monitored.

    Critical quality attributes
    A CQA is anything that can impact a drug’s safety, efficacy, and quality. ICH Q8 defines it as “a physical chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.” All identified CQAs are linked to critical process parameters, based on the risk assessment that is carried out, and a final list of CQAs is generated to map the control strategy. A list of typical CQAs for a monoclonal antibody is shown in Table 1.


    Table 1. Typical CQAs for a monoclonal antibody

    If the molecule is not yet well characterized in the clinic or by biochemical and other testing, an additional risk assessment should be carried out to identify any new CQAs and critical process parameters that should be included. Either way, process characterization and design of experiments (DoE) will be applied.

    Determining the CQAs should be one of the first tasks in a process characterization. It is important to remember that not all molecules – even if they are the same type of molecule, such as a monoclonal antibody – will have the same CQAs. It is, therefore, essential to assess all the knowledge that has been gained about the molecule from early development work to ensure all the CQAs have been correctly identified.

    Although it is possible to make some assumptions with regard to typical CQAs, they are very specific for the individual molecule and every CQA should be associated with critical process parameters to characterize the process and generate a control strategy. This control strategy is a regulatory requirement, and its main objective is to demonstrate that there is a process that will achieve the required quality for the product.

    Based on a criticality risk assessment, a testing plan that is based on the criticality of product attributes should be established. Each CQA should have at least one analytical method, batch record instruction or in process control (IPC), and frequency of monitoring associated with it. Analytical control measurements can be made in-process, for release, after stability testing, and as part of the characterization process. Some CQAs will need to be checked at all of these four stages, such as the absence of aggregates. Others will only be required at certain points; Immunoglobulin G (IgG) concentration, for example, will need to be measured in-process and at release, and protein identification via peptide mapping will only be required as part of the characterization process.

    Some critical process parameters are of a higher risk than others, and at the outset of a process, thoughtful consideration must be given to what represents “acceptable risk” and what does not. There are process parameters that might not impact any of the CQAs but may still affect process performance and will need to be evaluated. Scores from the risk assessment will be used to decide exactly which parameters will be evaluated during the process characterization experiment. Since all the experiments will be on a smaller scale than the final process, a scaled-down model for the process characterization work will be required.

    Different types of experiments can be performed during process characterization, including one-factor-at-a-time (OFAT), multi-factor experiments and DoEs. Depending on the objective and knowledge of the process, there are multiple types of DoEs that can be performed and full factorial and fractional factorial are the screening designs that are traditionally used. Definitive screening design is a relatively new approach, which targets screening with some potential to identify optimization opportunities.  Ultimately, a risk matrix is defined for every operation, and many different studies can be included in this matrix. Table 2 shows an example of this type of matrix for a bioreactor and includes both the process parameters and the categorization from the risk analysis, as well as the impact the process parameters have, and the recommended studies to establish the control strategy.


    Table 2. Example Study Recommendations and Supporting Analytical Requirments

    Careful process characterization is important in the successful completion of pivotal manufacturing batches for Phase 3 trials to take place, and PPQ is an important step. The ICH guidelines serve as a high-level guideline,   however, there are many different approaches to the detailed planning of a PPQ master plan and scheduled GMP batches, and companies can build on their experience and be led by regulatory guidelines to enable the development of best practices.

    Figure 1 gives a general timeline for the filing and approval of large molecules, condensing the points down into key outcomes and key deliverables. There are approaches to hasten development that may come with accelerated approvals and encouraging data from proof-of-concept clinical trials. Efforts to both understand the process, improve and validate methods, and beginning process characterization can be done in parallel in preparation for pivotal batches. A key consideration at this point is to avoid major changes if possible, and to begin stability studies as early as possible. Lessons learned from the process characterization, and the full understanding of the molecule and its critical attributes are the surest means of successful approval and lifecycle of the product. The earlier the process is confirmed, the more likely that changes will only be required if unexpected results and outcomes were to occur. Once all this is completed, primary stability drug substance and drug product batches can be made that will be used for the final process formulation and for fill–finish development. Other considerations to be made at this point will be the container, closure, and other aspects such as the requirement for a syringe.


    Figure 1. Filing and Approval - General Timeline for Large Molecule Drug Substance (DS) and Drug Product (DP)

    Batches for stability testing will also be made, and at this point there are considerable time pressures, not least because a minimum of six months’ stability data is usually required for the biologics license application (BLA) filing. Regulatory bodies are looking to ensure the information on the process is all present and acceptable, so the data from the manufacturing batches, allied to the control strategy and the linkage of CQAs, will all be required for final approval. Ultimately, the solution requires a thorough understanding of the risks and what level of risk will be acceptable.

    Conclusion
    Process validation is a critical step of late-phase development in preparation for commercial launch. Navigating this step quickly and successfully requires integrated planning, timely execution and a deep knowledge of the process and molecule. A thorough understanding of both risk and commercial needs of the molecule also need to be taken into consideration during this pivotal time. Ultimately, it is important to maintain a line-of-sight from clinical development to commercial manufacturing with a view to patient impact. CP

    References
    1. https://www.fda.gov/downloads/drugs/guidances/ucm070336.pdf – Guidance for Industry – Process Validation: General Principles and Practices; FDA January 2011
    2. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf
    Related Searches
    • equipment
    • process control
    • biologics
    • formulation
    Suggested For You
    Eurofins PSS Insourcing Solutions Eurofins PSS Insourcing Solutions
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    5 ADC Manufacturing Challenges You Need To Know 5 ADC Manufacturing Challenges You Need To Know
    Nitrosamines Nitrosamines
    Micro-Sphere Partners With PTM Consulting Micro-Sphere Partners With PTM Consulting
    ISPE Releases Good Practice Guide: Process Validation ISPE Releases Good Practice Guide: Process Validation
    Pii Receives EIR From FDA Pii Receives EIR From FDA
    3P Enters Mfg. Tie-up With Dutch Biotech Xenikos 3P Enters Mfg. Tie-up With Dutch Biotech Xenikos
    Support Services Support Services
    Catalent Enters Clinical Supply Partnership with Adial Catalent Enters Clinical Supply Partnership with Adial
    Former FDA Senior Executives Join PAREXEL Former FDA Senior Executives Join PAREXEL
    Heritage Pharma Labs Bolsters Portfolio Heritage Pharma Labs Bolsters Portfolio
    FDA & Data Integrity FDA & Data Integrity
    Lonza Supplies Portola’s Second-Gen Andexxa Lonza Supplies Portola’s Second-Gen Andexxa

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20


    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20


    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20

    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20


    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20

    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Catalent Biologics Completes Madison Expansion
    • ANI Acquires Branded Products Portfolio From Sandoz
    Breaking News
    • Catalent Biologics Completes Madison Expansion
    • Lonza Expands PyroTec PRO for Endotoxin Testing
    • FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    • Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    • Lilly Modifies Purchase Agreement with U.S. for COVID Therapies
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    4-week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study
    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    KD Pharma Acquires Rohner AG Manufacturing Assets
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Sika Expands Production Capacity in Qatar
    Sto Corp. ISO Certifications Extended
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MICRO Expands with New Facility in Costa Rica
    DiaSorin to Buy Luminex for $1.8B
    Endologix Acquires PQ Bypass
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Catalent Biologics Completes Madison Expansion
    Lonza Expands PyroTec PRO for Endotoxin Testing
    FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revieve Launches Skin Coach
    Carlyle Group Acquires Majority Stake in Beautycounter
    The Honest Co. Files for an Initial Public Offering
    Happi

    Latest Breaking News From Happi

    Babor Professional Skin Care Names McCaffrey as Vice President of Sales
    Diamond Chemical Appoints Technical Service Representative
    Carlyle To Acquire Majority Stake in Beautycounter
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Enprom helps converter respond to flexible packaging needs
    anytron assists medical device company with labeling
    Dantex debuts new capabilities with white ink opacity
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Aries Face Masks Meet ASTM Standards
    Tufropes Launches Inherently Antibacterial and Antimicrobial Spunbond
    NXTNano Adding Three Lines
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    SynerFuse, Cirtec Medical Partner to Develop Back Pain Management Device
    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    First Solar Series 6 CuRe has Industry’s Lowest Warranted Degradation Rate
    SEMI: 2020 Global Semiconductor Equipment Sales Surge 19% to Industry Record $71.2 Billion

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login